GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eyenovia Inc (NAS:EYEN) » Definitions » Return-on-Tangible-Equity

Eyenovia (Eyenovia) Return-on-Tangible-Equity : -3,398.52% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Eyenovia Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Eyenovia's annualized net income for the quarter that ended in Mar. 2024 was $-43.69 Mil. Eyenovia's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $1.29 Mil. Therefore, Eyenovia's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -3,398.52%.

The historical rank and industry rank for Eyenovia's Return-on-Tangible-Equity or its related term are showing as below:

EYEN' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -381.12   Med: -147.87   Max: -71.44
Current: -381.12

During the past 9 years, Eyenovia's highest Return-on-Tangible-Equity was -71.44%. The lowest was -381.12%. And the median was -147.87%.

EYEN's Return-on-Tangible-Equity is ranked worse than
93.33% of 1305 companies
in the Biotechnology industry
Industry Median: -47.16 vs EYEN: -381.12

Eyenovia Return-on-Tangible-Equity Historical Data

The historical data trend for Eyenovia's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eyenovia Return-on-Tangible-Equity Chart

Eyenovia Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only -147.87 -146.20 -71.44 -148.59 -226.13

Eyenovia Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -138.92 -188.82 -242.82 -310.41 -3,398.52

Competitive Comparison of Eyenovia's Return-on-Tangible-Equity

For the Biotechnology subindustry, Eyenovia's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eyenovia's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eyenovia's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Eyenovia's Return-on-Tangible-Equity falls into.



Eyenovia Return-on-Tangible-Equity Calculation

Eyenovia's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-27.261/( (17.235+6.876 )/ 2 )
=-27.261/12.0555
=-226.13 %

Eyenovia's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-43.688/( (6.876+-4.305)/ 2 )
=-43.688/1.2855
=-3,398.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Eyenovia  (NAS:EYEN) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Eyenovia Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Eyenovia's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Eyenovia (Eyenovia) Business Description

Industry
Traded in Other Exchanges
N/A
Address
295 Madison Avenue, Suite 2400, New York, NY, USA, 10017
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
Executives
Michael M Rowe director, officer: Chief Executive Officer C/O EYENOVIA, INC., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Ellen R Strahlman director ALTRIA GROUP, INC., 6601 W. BROAD STREET, RICHMOND VA 23230
Stuart M. Grant 10 percent owner 11 SUMMIT LANE, GREENVILLE DE 19807
Ram Palanki director C/O EYENOVIA, INC, 295 MADISON AVENUE SUITE 2400, NEW YORK NY 10017
Rachel Jacobson director C/O EYENOVIA INC, 295 MADISON AVENUE SUITE 2400, NEW YORK NY 10017
John P Gandolfo officer: Chief Financial Officer 62 TERRACE ROAD, WAYNE NJ 07470
Bren Kern officer: Chief Operating Officer 295 MADISON AVENUE, SUITE 2400, C/O EYENOVIA, INC., NEW YORK NY 10017
Mather Charles E Iv director C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Tsontcho Ianchulev director 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Stephen Keith Benjamin director 135 NORTH CHURCH STREET, SPARTANBURG SC 29306
Julia A Haller director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Lee Kenneth B Jr director 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
Curt H Labelle director C/O INVESTOR GROWTH CAPITAL, INC., 630 FIFTH AVENUE, SUITE 1965, NEW YORK NY 10011
Anthony Y Sun director C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10106
Fredric N Eshelman director PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401